Author:
Chen Weijie,Krainak Daniel,Sahiner Berkman,Petrick Nicholas
Abstract
AbstractThis chapter presents a regulatory science perspective on the assessment of machine learning algorithms in diagnostic imaging applications. Most of the topics are generally applicable to many medical imaging applications, while brain disease-specific examples are provided when possible. The chapter begins with an overview of US FDA’s regulatory framework followed by assessment methodologies related to ML devices in medical imaging. Rationale, methods, and issues are discussed for the study design and data collection, the algorithm documentation, and the reference standard. Finally, study design and statistical analysis methods are overviewed for the assessment of standalone performance of ML algorithms as well as their impact on clinicians (i.e., reader studies). We believe that assessment methodologies and regulatory science play a critical role in fully realizing the great potential of ML in medical imaging, in facilitating ML device innovation, and in accelerating the translation of these technologies from bench to bedside to the benefit of patients.
Reference88 articles.
1. Sahiner B, Pezeshk A, Hadjiiski LM, Wang X, Drukker K, Cha KH, Summers RM, Giger ML (2019) Deep learning in medical imaging and radiation therapy. Med Phys 46(1):e1–e36. https://doi.org/10.1002/mp.13264
2. Lui YW, Chang PD, Zaharchuk G, Barboriak DP, Flanders AE, Wintermark M, Hess CP, Filippi CG (2020) Artificial intelligence in neuroradiology: current status and future directions. Am J Neuroradiol 41(8):E52–E59. https://doi.org/10.3174/ajnr.A6681
3. U.S. Food and Drug Administration (2017) De Novo classification process (Evaluation of Automatic Class III Designation). Guidance for Industry and Food and Drug Administration Staff
4. U.S. Food and Drug Administration (2014) The 510(k) program: evaluating substantial equivalence in premarket notifications [510(k)]. Guidance for Industry and Food and Drug Administration Staff
5. U.S. Food and Drug Administration (2012) Factors to consider when making benefit-risk determinations in medical device premarket approval and De Novo classifications. Guidance for Industry and Food and Drug Administration Staff